ACE activity is modulated by the enzyme α-galactosidase A

Journal of Molecular Medicine

Volumn 89, Issue 1, 2011, Pages 65-74

  Batista, Elice Carneiro ^a   Carvalho, Luiz Roberto ^b   Casarini, Dulce Elena ^a   Carmona, Adriana Karaoglanovic ^a   Dos Santos, Edson Lucas ^c   Da Silva, Elton Dias ^a   Dos Santos, Robson Augusto ^d   Nakaie, Clovis Ryuichi ^a   Rojas, Maria Verônica Munoz ^e   De Oliveira, Suzana MacEdo ^a   Bader, Michael ^f   D'Almeida, Vânia ^a   Martins, Ana Maria ^a   De Picoly Souza, Kely ^c   Pesquero, João Bosco ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Hospital São Vicente de Paulo   (Brazil)

^c UNIVERSIDADE FEDERAL DA GRANDE DOURADOS   (Brazil)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^e Personalized Genetic Health   (Brazil)

^f MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

galactosidase A; ACE; ACE inhibitors; Angiotensin; Angiotensin I converting enzyme; Biochemistry; Biology; Blood pressure; Fabry disease

Indexed keywords

AGALSIDASE BETA; ALPHA GALACTOSIDASE; ANGIOTENSIN I; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RECOMBINANT ALPHA GALACTOSIDASE A; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; HUMAN; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; UPREGULATION;

ADOLESCENT; ADULT; ALPHA-GALACTOSIDASE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINS; ANIMALS; BLOOD PRESSURE; CHO CELLS; CRICETINAE; CRICETULUS; FABRY DISEASE; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MALE; MIDDLE AGED; MODELS, ANIMAL; PEPTIDYL-DIPEPTIDASE A; RABBITS; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 78651348512     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-010-0686-2     Document Type: Article

References (48)

1. RO Brady AE Gal RM Bradley E Martensson AL Warshaw L Lastes 1967 Enzymatic defect in Fabry's disease Ceramidetrihexosidase deficiency N Engl J Med 276 21 1163 1167 1:STN:280:DyaF2s7jsFWltQ%3D%3D 10.1056/NEJM196705252762101 6023233
2. D Bloom D Speijer GE Linthosrt WG Donker-Koopman A Strijland JMFG Aerts 2003 Recombinant enzyme therapy for Fabry disease: absence of editing of human α-galactosidase A mRNA Am J Hum Genet 72 23 31 10.1086/345309
3. TR Clarke 2007 Narrative review: Fabry disease Ann Intern Med 146 425 433 17371887
4. RO Brady R Schiffmann 2000 Clinical features of and recent advances in therapy for Fabry disease Jama 284 2771 2775 1:STN:280:DC%2BD3M%2Fms1Gntg%3D%3D 10.1001/jama.284.21.2771 11105184
5. Desnick RJ, Ioannou YA, Eng CM (2001) α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular basis of inherited disease, 8th edn. McGraw-Hill, New York, pp 3733-3774
6. F Matsuzawa SI Aikawa H Doi T Okumiya H Sakuraba 2005 Fabry disease: correlation between structural changes in α-galactosidase, and clinical and biochemical phenotypes Hum Genet 117 317 338 1:CAS:528:DC%2BD2MXmvFWisbg%3D 10.1007/s00439-005-1300-5 15924232
7. KD MacDermot A Holmes AH Miners 2001 Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males J Med Genet 38 750 760 1:STN:280:DC%2BD3MnktFOlsA%3D%3D 10.1136/jmg.38.11.750 11694547
8. GM Altarescu LG Goldfarb KY Park C Kaneski N Jeffries S Litvalk JW Nagle R Schiffmann 2001 Identification of fifteen novel mutations and genotype-phenotype relationship in Fabry disease Clin Genet 60 46 51
9. RS Desnick R Brady J Barrenger AJ Collins DP Germain M Goldman G Grabowsiki S Packman WR Wilcose 2003 Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy Ann Intern Med 138 338 346 12585833
10. MH Branton R Schiffmann SG Sabnis GJ Murray JM Quirk G Altarescu L Goldfarb RO Brady JE Balow HA Austin III, et al. 2002 Natural history of Fabry renal disease: influence of alfa-galactosidase A activity and genetic mutations on clinical course Medicine 81 122 138 1:CAS:528:DC%2BD38Xis1alsbc%3D 10.1097/00005792-200203000-00003 11889412
11. KD MacDermot A Holmes AH Miners 2001 Natural history of Fabry disease in affected males and obligate carrier females J Inherit Metab Dis 24 2 13 14 10.1023/A:1012447102358 11758673
12. AC Vedder GE Linthorst MJ van Breemen JEM Groener FJ Bemelman A Strijland MMAM Mannens JMFG Aerts CEM Hollak 2007 The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels J Inherit Metab Dis 30 68 78 1:CAS:528:DC%2BD2sXnsFyktw%3D%3D 10.1007/s10545-006-0484-8 17206462
13. JM Aerts JE Groener S Kuiper WE Donker-Koopman A Strijland R Ottenhoff C Van Roomen M Mirzaian FA Wijburg GE Linthorst, et al. 2008 Elevated globotriaosylsphingosine is a hallmark of Fabry disease PNAS 105 8 2812 2817 1:CAS:528:DC%2BD1cXjtVSjurY%3D 10.1073/pnas.0712309105 18287059
14. CM Eng N Guffon WR Wilcox DP Germain P Lee S Waldek L Caplan GE Linthorst RJ Desnick 2001 Safety and efficacy of recombinant human alfa-galactosidase A replacement therapy in Fabry's disease N Engl J Med 345 9 16 1:CAS:528:DC%2BD3MXltlKisro%3D 10.1056/NEJM200107053450102 11439963
15. R Schiffmann JB Kopp HA Austin III S Sabnis DF Moore T Weibel JE Balow RO Brady 2001 Enzyme replacement therapy in Fabry disease: a randomized controlled trial JAMA 285 2743 2749 1:STN:280:DC%2BD3MzltVCgsg%3D%3D 10.1001/jama.285.21. 2743 11386930
16. KD MacDermot A Holmes AH Miners 2001 Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females J Med Genet 38 769 775 1:STN:280:DC%2BD3MnosFyisw%3D%3D 10.1136/jmg.38.11.769 11732485
17. AC Vedder GE Linthorst G Houge JEM Groener EE Ormel BJ Bouma JMFG Aerts A Hirth CEM Hollak 2007 Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg PLoS ONE 2 7 e598 10.1371/journal.pone.0000598 10.1371/journal.pone.0000598 17622343
18. CM Eng DP Germain BM DP DG Warnock C Wanner RJ Hopkin J Bultas P Lee K Sims, et al. 2006 Fabry disease: guidelines for the evaluation and management of multiorgan system involvement Genet Med 8 9 539 548 10.1097/01.gim.0000237866. 70357.c6 16980809
19. KK Griedling TJ Murphy RW Alexander 1993 Molecular biology of the renin-angiotensin system Circulation 87 1816 1828
20. DW Cushman HS Cheung 1971 Concentration of angiotensin converting enzyme in tissues of rat BBA 250 261 265 1:CAS:528:DyaE38Xht1egsg%3D%3D 4334856
21. FAO Mendelsohn AM Allen SY Chai MJ McKinley BJ Oldfield G Paxinos 1990 The brain angiotensin system: insights from mapping its components Trends Endocrinol Metab 1 189 197 1:STN:280:DC%2BD1c3ltVGhsQ%3D%3D 10.1016/1043- 2760(90)90052-5 18411117
22. M Carluccio M Soccio R De Caterina 2001 Aspects of gene polymorphisms in cardiovascular disease: the renin-angiotensin system Eur J Clin Invest 31 476 488 1:CAS:528:DC%2BD3MXlt1SrtLc%3D 10.1046/j.1365-2362.2001.00839.x 11422397
23. MC Araujo RL Melo MH Cesari MA Juliano L Juliano AK Carmona 2000 Peptidase specificity characterization of C- and N-terminal catalytic sites of angiotensin I-converting enzyme Biochemistry 39 8519 8525 1:CAS:528: DC%2BD3cXkt1yrsbw%3D 10.1021/bi9928905 10913258
24. FA Ronchi MC Andrade AK Carmona JE Krieger DE Casarini 2005 N-domain angiotensin-converting enzyme isoform expression in tissues of Wistar and spontaneously hypertensive rats J Hypertens 23 10 1793 1794 10.1097/01.hjh. 0000183523.66123.95
25. RA Sabatini PA Bersanetti SL Farias L Juliano MA Juliano DE Casarini AK Carmona ACM Paiva JB Pesquero 2007 Determination of angiotensin I-converting enzyme activity in cells in culture using fluorescence resonance energy transfer peptides Anal Biochem 363 255 262 1:CAS:528:DC%2BD2sXjsVWiu7k%3D 10.1016/j.ab.2007.01.020 17320031
26. OH Lowry NJ Rosebrough AL Farr RJ Randall 1951 Protein measurement with the Folin phenol reagent J Biol Chem 1 265 275
27. B Hoffmann 2009 Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring Orphanet J Rare Dis 4 21 10.1186/1750-1172-4-21 19818152
28. JT Wright G Bakris JT Wright G Bakris T Greene LY Agodoa LJ Appel J Charleston D Cheek JG Douglas-Baltimore 2002 African American study of kidney disease and hypertension study group: effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial JAMA 288 2421 2431 1:CAS:528:DC%2BD38XoslOktr8%3D 10.1001/jama.288.19.2421 12435255
29. G Remuzzi P Ruggenenti N Perico 2002 Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition Ann Intern Med 136 604 1:CAS:528:DC%2BD38XjsVKgu7Y%3D 11955029
30. AD Rule TS Larson EJ Bergstralh JM Slezak SJ Jacobsen FG Cosio 2004 Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease Ann Intern Med 12 929 937
31. P Ruggenenti A Perna G Gherardi R Benini G Remuzzi 2000 Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury Am J Kidney Dis 35 1155 1165 1:CAS:528:DC%2BD3cXks1Shtbo%3D 10.1016/S0272-6386(00)70054-0 10845831
32. PA Sarafidis N Khosla GL Bakris 2007 Antihypertensive therapy in the presence of proteinuria Am J Kidney Dis 49 12 26 1:CAS:528:DC%2BD2sXhsFSjsLo%3D 10.1053/j.ajkd.2006.10.014 17185142
33. Warnock DG (2009) Optimizing treatment to reach therapeutic goals in Fabry disease. Clinical Therapeutics 31, Supplement A
34. H Tahir LL Jackson DG Warnock 2007 Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta J Am Soc Nephrol 18 2609 2617 1:CAS:528:DC%2BD2sXhtV2murvN 10.1681/ASN.2006121400 17656478
35. H Sakuraba M Murata-Ohsawa I Kawashima Y Tajima M Kotani T Ohshima Y Chiba M Takashiba Y Jigami T Fukushige 2006 Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice J Hum Genet 51 180 188 1:CAS:528:DC%2BD28Xis1Oktr8%3D 10.1007/s10038-005-0342-9 16372133
36. R Schiffmann H Askari M Timmons C Robinson W Benko RO Brady M Ries 2007 Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing J Am Soc Nephrol 18 1576 1583 1:CAS:528:DC%2BD2sXls1Gksrw%3D 10.1681/ASN.2006111263 17409308
37. B Baudin N Alves A Pilon B Beneteau-Burnat J Giboudeau 1997 Structural and biological roles of glycosylation in pulmonary angiotensin I-converting enzyme Glycobiology 7 565 570 1:CAS:528:DyaK2sXjvVKnsL0%3D 10.1093/glycob/7.4. 565 9184838
38. R Ramchandran S Kasturi JG Douglas I Sen 1996 Metalloprotease-mediated cleavage secretion of pulmonary ACE by vascular endothelial and kidney epithelial cells Am J Physiol 271 H744 H751 1:CAS:528:DyaK28XlsFars7s%3D 8770118
39. R Sadhukhan KR Santhamma P Reddy JJ Peschon RA Black I Sen 1999 Unaltered cleavage and secretion of angiotensin-converting enzyme in tumor necrosis factor-alphaconverting enzyme-deficient mice J Biol Chem 274 10511 10516 1:CAS:528:DyaK1MXis1Gisr8%3D 10.1074/jbc.274.15.10511 10187843
40. F Soubrier F Alhenc-Gelas C Hubert J Allegrini M John G Tregear P Corvol 1988 Two putative active centers in human angiotensin I converting enzyme revealed by molecular cloning Proc Natl Acad Sci 85 9386 9390 1:CAS:528:DyaL1MXlt1OqsLs%3D 10.1073/pnas.85.24.9386 2849100
41. JE Ripka JW Ryan FA Valido AYK Chung CM Peterson RL Urry 1993 N-glycosylation of forms of angiotensin converting enzyme from four mammalian species Biochem Biophys Res Commun 196 503 508 1:CAS:528:DyaK2cXis1ehsQ%3D%3D 10.1006/bbrc.1993.2278 8240320
42. XC Yu ED Sturrock Zh Wu K Biemann MRW Ehlers JF Riordan 1997 Identification of N-linked glycosylation sites in human testis angiotensin-converting enzyme and expression of an active deglycosylated form J Biol Chem 272 3511 3519 1:CAS:528:DyaK2sXhtFeks74%3D 10.1074/jbc.272.6.3511 9013598
43. OA Kost NV Bovin EE Chemodanova VV Nasonov TA Orth 2000 New feature of angiotensin-converting enzyme: carbohydrate-recognizing domain J Mol Recognit 13 360 369 1:CAS:528:DC%2BD3cXosFOisbs%3D 10.1002/1099-1352(200011/12)13:6<360: :AID-JMR508>3.0.CO;2-K 11114069
44. HR Gralnick WS Kramer LP McKeown L Garfinkel A Pinot SB Williams H Krutzsch 1996 Platelet adhesion at high shear rates: the roles of von Willebrand factor/GPIb and the beta 1 integrin alpha 2 beta 1 Thromb Res 81 1 113 119 1:CAS:528:DyaK28XivFemtA%3D%3D 10.1016/0049-3848(95)00219-7 8747526
45. JM Conroy JM Hartley RL Soffer 1978 Canine pulmonary angiotensin- converting enzyme: Physicochemical, catalytic and immunological properties Biochim Biophys Acta 524 403 412 1:CAS:528:DyaE1cXkslagtLc%3D 208622
46. T Orth S Voronov P Binevski W Saenger OA Kost 1998 Glycosylation of bovine pulmonary angiotensin-converting enzyme modulates its catalytic properties FEBS Lett 431 255 258 1:CAS:528:DyaK1cXks1Kqt7c%3D 10.1016/S0014-5793(98)00767-4 9708914
47. P Corvol TA Williams F Soubrier 1995 Dipeptidyl dipeptidase: angiotensin-converting enzyme Meth Enzymol 248 283 305 1:CAS:528: DyaK2MXptVShsrk%3D 10.1016/0076-6879(95)48020-X 7674927
48. MRW Ehlers JF Riordan 1989 Angiotensin-converting enzyme: new concepts concerning its biological role Biochemistry 28 5318 5322 10.1021/bi00439a001